> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Insmed Third-Quarter Revenue Hits $524.4 Million, And It Lifts The Floor On 2026 Sales Guidance For Both Drugs
- URL: https://www.bullished.co/insmed-third-quarter-revenue-hits-524-4-million-and-it-lifts-the-floor-on-2026-sales-b5f4d5cc/
- Published: 2026-10-29T11:41:00.000Z
- Updated: 2026-10-29T11:41:00.000Z
- Description: Brinsupri sales rose 29% from the second quarter, and the net loss narrowed to $100.3 million from $370.0 million a year earlier.
- Author: Matteo Parrino
- Tags: Earnings, INSM, Industry: Healthcare

[Insmed](https://www.bullished.co/tag/insm/), the biopharmaceutical company that sells Brinsupri and Arikayce, reported third-quarter revenue of [$524.4 million](https://www.sec.gov/Archives/edgar/data/0001104506/000114036126041097/ef20084500%5F8k.htm?ref=bullished.co), up 268% from $142.3 million a year earlier, and raised the low end of its 2026 sales guidance for both drugs. The results came in an [8-K](https://www.bullished.co/learn/8-k-items-explained/) filed Thursday.

## Brinsupri carries the quarter

Brinsupri, a once-daily tablet for non-cystic fibrosis bronchiectasis (a chronic lung disease), brought in [$400.1 million](https://www.sec.gov/Archives/edgar/data/0001104506/000114036126041097/ef20084500%5Fex99-1.htm?ref=bullished.co), up 29% from the second quarter. The company said growth was driven by the U.S. market. Brinsupri's U.S. sales were $398.1 million.

Arikayce, an inhaled antibiotic for a rare lung infection, had sales of [$124.4 million](https://www.prnewswire.com/news-releases/insmed-reports-third-quarter-2026-financial-results-and-provides-business-update-302922707.html?ref=bullished.co), up 9% from the third quarter of 2025\. International sales rose 21% to $48.9 million, while U.S. sales rose 2% to $75.5 million.

Chief Executive Will Lewis said Brinsupri's U.S. launch "continues to exceed expectations."

## Guidance floors move up

Insmed now expects full-year Brinsupri revenue of [$1.35 billion](https://www.prnewswire.com/news-releases/insmed-reports-third-quarter-2026-financial-results-and-provides-business-update-302922707.html?ref=bullished.co) to $1.4 billion, up from a prior range of $1.25 billion to $1.4 billion. Arikayce guidance is $460 million to $470 million, from $450 million to $470 million. Only the low ends moved.

Brinsupri sales have climbed from $144.6 million in the fourth quarter of 2025 to $207.9 million in the first quarter and $309.2 million in the second quarter of 2026, according to the [earnings presentation](https://www.sec.gov/Archives/edgar/data/0001104506/000114036126041097/ef20084500%5Fex99-2.htm?ref=bullished.co). The company said its Brinsupri guidance does not count meaningful revenue from Japan in 2026.

Insmed launched Brinsupri in Japan in October, after Japan's health ministry approved it in August.

## A narrower loss, still heavy spending

The net loss was $100.3 million, or [$0.46 per share](https://seekingalpha.com/news/4660061-insmed-gaap-eps-of-0%5F46-misses-by-0%5F08-revenue-of-524%5F4m-beats-by-24%5F92m?ref=bullished.co), against $370.0 million, or $1.75 per share, a year earlier. Research and development spending rose to $270.0 million from $186.4 million, and selling, general and administrative costs rose to $253.0 million from $186.4 million. Insmed tied the increases to the Brinsupri launch and to its late-stage treprostinil palmitil inhalation powder studies.

Cash, cash equivalents and marketable securities were about $1.1 billion at September 30\. The company said it believes it can reach positive cash flow in 2027 without raising more capital.

## Dates on the calendar

The FDA granted priority review to an application to expand Arikayce's use in Mycobacterium avium complex lung disease and set a target action date of January 28, 2027\. Insmed plans to submit Japanese regulatory data in the fourth quarter of 2026.

The FDA's January 28, 2027 target date for the Arikayce expansion is the next decision point.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — INSMED Inc (INSM)](https://www.sec.gov/Archives/edgar/data/0001104506/000114036126041097/ef20084500%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ef20084500\_ex99-1.htm — INSMED Inc 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001104506/000114036126041097/ef20084500%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ef20084500\_ex99-2.htm — INSMED Inc 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001104506/000114036126041097/ef20084500%5Fex99-2.htm?ref=bullished.co) — SEC EDGAR
- [Insmed GAAP EPS of -$0.46 misses by $0.08, revenue of $524.4M beats by $24.92M (INSM:NASDAQ)](https://seekingalpha.com/news/4660061-insmed-gaap-eps-of-0%5F46-misses-by-0%5F08-revenue-of-524%5F4m-beats-by-24%5F92m?ref=bullished.co) — seekingalpha.com
- [Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update](https://www.prnewswire.com/news-releases/insmed-reports-third-quarter-2026-financial-results-and-provides-business-update-302922707.html?ref=bullished.co) — prnewswire.com

### More on Insmed

- [Insmed Says It Won't Build A Traditional European Sales Operation For BRINSUPRI](https://www.bullished.co/insmed-says-it-wont-build-a-traditional-european-sales-operation-for-brinsupri-7bd53000/)
- [Insmed Names Ex-Sanofi CEO Paul Hudson And Verily Health CFO Utpal Koppikar To Its Board](https://www.bullished.co/insmed-names-ex-sanofi-ceo-paul-hudson-and-verily-health-cfo-utpal-koppikar-to-its-board-26c095be/)
- [Insmed CFO Sara Bonstein To Leave October 30, Staying Through The Earnings Call](https://www.bullished.co/insmed-cfo-sara-bonstein-to-leave-october-30-staying-through-the-earnings-call-d0f10ddb/)

[All Insmed (INSM) coverage →](https://www.bullished.co/tag/insm/)